Ovidrel Side Effects

Please note - some side effects for Ovidrel may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).

Side Effects of Ovidrel - for the consumer

Ovidrel

All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome when using Ovidrel:

Nausea; pain, swelling, bruising, or redness at the injection site; vomiting.

Severe allergic reactions (rash; hives; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); bloating or swelling in the stomach or pelvic area; breast pain; chest pain; infrequent urination; irregular heartbeat; leg pain; persistent or severe nausea, vomiting, or diarrhea; severe pelvic pain; stomach pain; sudden shortness of breath; weight gain.

For the professional

Ovidrel

The safety of Ovidrel® was examined in four clinical studies that treated 752 patients of whom 335 received Ovidrel® 250 μg following follicular recruitment with gonadotropins. When patients enrolled in four clinical studies (3 in ART and one in OI) were injected subcutaneously with either Ovidrel® or an approved urinary-derived hCG, 14.6 % (49 of 335 patients) in the Ovidrel® 250 μg group experienced application site disorders compared to 28% (92 of 328 patients) in the approved u-hCG group. Adverse events reported for Ovidrel® 250 μg occurring in at least 2% of patients (regardless of causality) are listed in Table 9 for the 3 ART studies and in Table 10 for the single OI study.

Adverse events not listed in Table 9 that occurred in less than 2% of patients treated with Ovidrel® 250 μg whether or not considered causally related to Ovidrel®, included: injection site inflammation and reaction, flatulence, diarrhea, hiccup, ectopic pregnancy, breast pain, intermenstrual bleeding, vaginal hemorrhage, cervical lesion, leukorrhea, ovarian hyperstimulation, uterine disorders, vaginitis, vaginal discomfort, body pain, back pain, fever, dizziness, headache, hot flashes, malaise, paraesthesias, rash, emotional lability, insomnia, upper respiratory tract infection, cough, dysuria, urinary tract infection, urinary incontinence, albuminuria, cardiac arrhythmia, genital moniliasis, genital herpes, leukocytosis, heart murmur and cervical carcinoma.

Additional adverse events not listed in Table 10 that occurred in less than 2% of patients treated with Ovidrel® 250 μg, whether or not considered causally related to Ovidrel®, included: breast pain, flatulence, abdominal enlargement, pharyngitis, upper respiratory tract infection, hyperglycemia and pruritis.

The following medical events have been reported subsequent to pregnancies resulting from hCG therapy in controlled clinical studies:

1. Spontaneous Abortion

2. Ectopic Pregnancy

3. Premature Labor

4. Postpartum Fever

5. Congenital abnormalities

Of 125 clinical pregnancies reported following treatment with FSH and Ovidrel® 250 μg or 500 μg, three were associated with a congenital anomaly of the fetus or newborn. Among patients receiving Ovidrel® 250 μg, cranial malformation was detected in the fetus of one woman and a chromosomal abnormality (47, XXX) in another. These events were judged by the investigators to be of unlikely or unknown relation to treatment. These three events represent an incidence of major congenital malformations of 2.4%, which is consistent with the reported rate for pregnancies resulting from natural or assisted conception. In a woman who received Ovidrel® 500 μg, one birth in a set of triplets was associated with Down’s syndrome and atrial septal defect. This event was considered to be unrelated to the study drug.

The following adverse reactions have been previously reported during menotropin therapy:

1. Pulmonary and vascular complications

2. Adnexal torsion (as a complication of ovarian enlargement)

3. Mild to moderate ovarian enlargement

4. Hemoperitoneum

There have been infrequent reports of ovarian neoplasms, both benign and malignant, in women who have undergone multiple drug regimens for ovulation induction; however, a causal relationship has not been established.

Ovidrel Injection

The safety of Ovidrel®  was examined in four clinical studies that treated 752 patients of whom 335 received Ovidrel® 250 μg following follicular recruitment with gonadotropins. When patients enrolled in four clinical studies (3 in ART and one in OI) were injected subcutaneously with either Ovidrel® or an approved urinary-derived hCG, 14.6%  (49 of 335 patients) in the Ovidrel® 250 μg group experienced application site disorders compared to 28% (92 of 328 patients) in the approved u-hCG group.  Adverse events reported for Ovidrel®  250 μg occurring in at least 2% of patients (regardless of causality) are listed in Table 9 for the 3 ART studies and in Table 10 for the single OI study.

Adverse events not listed in Table 9 that occurred in less than 2% of patients treated with Ovidrel® 250 μg whether or not considered causally related to Ovidrel®, included:  injection site inflammation and reaction, flatulence, diarrhea, hiccup, ectopic pregnancy, breast pain, intermenstrual bleeding, vaginal hemorrhage, cervical lesion, leukorrhea, ovarian hyperstimulation, uterine disorders, vaginitis, vaginal discomfort, body pain, back pain, fever, dizziness, headache, hot flashes, malaise, paraesthesias, rash, emotional lability, insomnia, upper respiratory tract infection, cough, dysuria, urinary tract infection, urinary incontinence, albuminuria, cardiac arrhythmia, genital moniliasis, genital herpes, leukocytosis, heart murmur and cervical carcinoma.

Additional adverse events not listed in Table 10 that occurred in less than 2% of patients treated with Ovidrel® 250 μg, whether or not considered causally related to Ovidrel®, included:  breast pain, flatulence, abdominal enlargement, pharyngitis, upper respiratory tract infection, hyperglycemia and pruritis.

The following medical events have been reported subsequent to pregnancies resulting from hCG therapy in controlled clinical studies:

1. Spontaneous Abortion

2. Ectopic Pregnancy

3. Premature Labor

4. Postpartum Fever

5. Congenital abnormalities

Of 125 clinical pregnancies reported following treatment with FSH and Ovidrel® 250 μg or 500 μg, three were associated with a congenital anomaly of the fetus or newborn.  Among patients receiving Ovidrel® 250 μg, cranial malformation was detected in the fetus of one woman and a chromosomal abnormality (47, XXX) in another.  These events were judged by the investigators to be of unlikely or unknown relation to treatment.  These three events represent an incidence of major congenital malformations of 2.4%, which is consistent with the reported rate for pregnancies resulting from natural or assisted conception.  In a woman who received Ovidrel® 500 μg, one birth in a set of triplets was associated with Down’s syndrome and atrial septal defect.  This event was considered to be unrelated to the study drug.

The following adverse reactions have been previously reported during menotropin therapy:

1. Pulmonary and vascular complications

2. Adnexal torsion (as a complication of ovarian enlargement)

3. Mild to moderate ovarian enlargement

4. Hemoperitoneum

There have been infrequent reports of ovarian neoplasms, both benign and malignant, in women who have undergone multiple drug regimens for ovulation induction; however, a causal relationship has not been established.

Post-marketing Reports

Isolated cases of allergic reactions, manifesting mainly as mild reversible skin rashes have been reported in patients treated with Ovidrel® since market introduction.  The causal relationship is unknown.

More resources:

Hcg

Pregnyl

Ovidrel

Ovidrel - Includes detailed dosage instructions.

Chorex - Includes detailed dosage instructions.

Ovidrel

Novarel

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.